Oral Mucositis

Company announces clinical progress with CG53135 for oral mucositis

Published in Blood Weekly, November 4th, 2004

CuraGen Corp. (CRGN) announced that clinical data from the phase I trial for CG53135 for oral mucositis will be presented at the annual meeting of the American Society of Hematology (ASH) in December 2004 in San Diego, California.

"We are very pleased with the progress we have achieved with CG53135 for oral mucositis and look forward to sharing the results of our phase I program at ASH," stated William Hahne, MD, vice president of clinical development at CuraGen. "The clinical data we have obtained has sparked the interest of several investigators who are eager to work with us in phase II, and we are in the process of making the necessary preparations to transition the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2004-11-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry